# Long-term Safety Study of Brodalumab in Adults With Crohn's Disease

> **NCT01199302** · PHASE2 · TERMINATED · sponsor: **Amgen** · enrollment: 67 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **BIOLOGICAL:** Brodalumab

## Key facts

- **NCT ID:** NCT01199302
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-02-02
- **Primary completion:** 2011-10-18
- **Final completion:** 2011-10-18
- **Target enrollment:** 67 (ACTUAL)
- **Why stopped:** The study was terminated early based on an imbalance in worsening Crohn's disease in active treatment groups.
- **Last updated:** 2021-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01199302

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01199302, "Long-term Safety Study of Brodalumab in Adults With Crohn's Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01199302. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*